Gemtuzumab for measurable residual leukemia after initial treatment
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial studies whether fractionated gemtuzumab can eliminate tiny, hard-to-see leukemia cells left after standard chemotherapy. It targets adults with acute myeloid leukemia (AML) who have measurable residual disease (MRD) rather than active leukemia in the blood.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been diagnosed with AML (but not acute promyelocytic leukemia, or APL; and not biphenotypic AML)
- Your leukemia must be MRD-positive only (less than 5% blast cells in bone marrow) and meet criteria for a response like complete remission or CR with incomplete blood recovery
- Your MRD must be measurable using specific tests (flow cytometry and/or PCR/molecular tests and/or chromosome/cytogenetic tests)
- You must have had at least one cycle of standard induction chemotherapy before joining (you can join at different times after that as an adult)
- Your leukemia cells must have CD33 on them, and you must be age 18+ with good enough general functioning
- You must be well enough for treatment based on organ lab tests (kidney, liver) and you must be able to sign consent; pregnancy test must be negative if applicable
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking two drugs, ruxolitinib and azacitidine, after a reduced-intensity stem cell transplant can help prevent acute myeloid leukemia (AML) from returning. It is for patients who are in remission and at high risk of relapse.
This Phase 3 trial tests whether adding gemtuzumab to standard chemotherapy helps people with newly diagnosed, favorable-intermediate AML reduce “MRD” (very small remaining leukemia cells). If MRD levels drop more, it may lower the chance of relapse.
This trial tests a combination of drugs for people with AML who, after initial treatment, have very low levels of leukemia still present (called measurable residual disease or MRD). The goal is to wipe out these remaining cells and reduce the chance of the cancer coming back.
This trial studies whether combining two medicines—midostaurin and gemtuzumab (with standard chemotherapy)—can improve outcomes for newly diagnosed acute myeloid leukemia (AML). It is testing a first-line treatment plan tailored to specific genetic changes in the leukemia.
This trial tests a new drug, ziftomenib, combined with two standard chemotherapies (venetoclax and gemtuzumab) for children and young adults with acute myeloid leukemia (AML) that has come back or not responded to treatment. It looks for specific genetic changes in the leukemia cells.
This Phase 1 trial tests a new combination of CPX-351 plus gemtuzumab ozogamicin for people newly diagnosed with acute myeloid leukemia (AML). It aims to find a safe dose and see how well the treatment works, especially when the leukemia cells carry a target called CD33.
Hear when a new Acute Myeloid Leukemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.